Alligator Bioscience’s CEO Søren Bregenholt visited BioStock’s studio to talk about the promising interim data from the OPTIMIZE-1 phase II trial with mitazalimab in pancreatic cancer. The interim analysis shows an Objective Response Rate of 52 per cent and a Disease Control Rate of 91 per cent, further validating the potential of the drug candidate. Until the topline data is presented in Q1 2024, Alligator will continue the preparations for phase III and the dialogues with potential partners, as well as initiate discussions with regulatory authorities on possible accelerated development pathways.
Watch the interview with Alligator Bioscience’s CEO Søren Bregenholt below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.